Clinical safety of long-acting β2-agonist and inhaled corticosteroid combination therapy in COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 3, Issue 3, 2006, Pages 163-171

  Decramer, Marc ^a   Ferguson, Gary ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Pulmonary Research Institute of Southeast Michigan   (United States)

Author keywords

Chronic obstructive pulmonary disease; COPD; Glucocorticosteroids; Inhaled corticosteroids; Safety

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID; HYDROCORTISONE; LONG ACTING DRUG; PLACEBO; SALMETEROL; TRIAMCINOLONE ACETONIDE;

AGITATION; ANGINA PECTORIS; ASTHMA; BACKACHE; BONE DISEASE; BRONCHUS MUSCLE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED MYOPATHY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EYE DISEASE; FRACTURE; HEADACHE; HEALTH STATUS; HEART DISEASE; HEART FAILURE; HEART PALPITATION; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; INFLAMMATION; INTRAOCULAR PRESSURE ABNORMALITY; LUNG FUNCTION; MONOTHERAPY; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; OROPHARYNX CANDIDIASIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURPURA; RESPIRATORY AIRFLOW; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROAT IRRITATION; THRUSH; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GLUCOCORTICOIDS; HEART RATE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33746916438     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550600830263     Document Type: Review

References (68)

1. BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52:Suppl 5:S1-28.
2. GOLD. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease, Updated 2005. National Institutes of Health. National Heart, Lung and Blood Institute 2005: 〈www.goldcopd. com〉.
3. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59:120-125.
4. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
5. Seeman E, Melton LJ III, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75:977-983.
6. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr., Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497-1505.
7. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease:scientific review. JAMA 2003; 290:2301-2312.
8. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059-2073.
9. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-1022.
10. Dougherty JA, Didur BL, Aboussouan LS. Long-acting inhaled beta 2-agonists for stable COPD. Ann Pharmacother 2003; 37:1247-1255.
11. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004; 125:1726-1734.
12. Melloni B, Germouty J. The influence of a new beta agonist: formoterol on mucociliary function. Rev Mal Respir 1992; 9:503-507.
13. Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002; 110:S291-297.
14. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratorymucosa in vitro. Eur Respir J 1998; 11:86-90.
15. Dowling RB, Rayner CF, Rutman A, Jackson AD, Kanthakumar K, Dewar A, Taylor GW, Cole PJ, Johnson M, Wilson R. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997; 155:327-336.
16. NICE. Chronic Obstructive Pulmonary Disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004:59.
17. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953.
18. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease:the ISOLDE trial. Br Med J 2000; 320:1297-1303.
19. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomised controlled trial. Lancet 2003; 361:449-456.
20. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351:773-780.
21. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909.
22. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; CD001288.
23. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:342-344; discussion 344.
24. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:341-342; discussion 344.
25. Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 2005; 27:346-354.
26. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580-584.
27. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease:does the dose matter? Eur Respir J 2003; 21:260-266.
28. Anzueto A, McLaughlin T, Standford R. Initial treatment regimen and risk of hospitalisation in patients with chronic obstructive pulmonary disease. J COPD 2004; 1:205-214.
29. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60:992-997.
30. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; CD003794.
31. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919.
32. Hanania NA, Darken P, Horstman D, Reisner MD, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate 250mcg/salmeterol 50 mcg combined in the discus inhaler for the treatment of chronic obstrctive pulmonary disease. Chest 2003; 124:834-843.
33. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:74-81.
34. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2002; 166:1084-1091.
35. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293-1299.
36. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, Wilde E, Cowie RL, Williams D, Rousseau R. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulm Med 2006; 6:3.
37. Basyigit I, Yildiz F, Ozkara SK, Yildirim E, Boyaci H, Ilgazli A. Addition of inhaled corticosteroid on combined bronchodilator therapy in patients with COPD. Pulm Pharmacol Ther 2005; 18:422-426.
38. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2:67-74.
39. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20:819-825.
40. Mapel DW, Hurley JS, Roblin D, Roberts M, Davis KJ, Schreiner R, Frost FJ. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006; 100:595-609.
41. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24:206-210.
42. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309:265-268.
43. Gross NJ. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2001; 7:84-92.
44. Lee TA, Weiss KB. Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2004; 169:855-859.
45. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture:a population-based case-control study. Am J Respir Crit Care Med 2002; 166:1563-1566.
46. Johnell O, Pauwels R, Lofdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19:1058-1063.
47. Halpern MT, Schmier JK, Van Kerkhove MD, Watkins M, Kalberg CJ. Impact of long-term inhaled corticosteroid therapy on bone mineral density:results of a meta-analysis. Ann Allergy Asthma Immunol 2004; 92:201-207; quiz 207-208, 267.
48. Knobil K, Watkin S, Yates J, Darken P, Wire P. Fracture incidence from clinical trials of fluticasone propionate alone or in combination with salmeterol in the treatment of chronic obstructive pulmonary disease. Chest 2002; 122:43s.
49. Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005; 127:89-97.
50. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; CD003537.
51. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003; 87:1247-1251.
52. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150:11-16.
53. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97:169-176.
54. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122:86-95.
55. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate:absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51:400-409.
56. Rabe KF. State of the art in beta2-agonist therapy:a safety review of long-acting agents. Int J Clin Pract 2003; 57:689-697.
57. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol:a dose-response comparison in healthy subjects. Thorax 2000; 55:650-656.
58. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004; 27:689-715.
59. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415.
60. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD:A meta-analysis. Chest 2004; 125:2309-2321.
61. Malolepszy J, Boszormenyi Nagy G, Selroos O, Larsso P, Brander R. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. Eur Respir J 2001; 18:928-934.
62. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817-1824.
63. Daley-Yates PT, Majer-Teboul C, Prieur A, Minini P, Bidault R, Maison-Blanche P, Finck-Brentano C. Cardiovascular (CV) pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol (SALM) following single and repeated dosing in chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2003; 167:A319.
64. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists:cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65:1595-1610.
65. Knobil K, Yancey S, Kral K, Rickard K. Salmeterol multi-center asthma research trial (SMART):Results from an interim analysis. Chest 2003; 124:335S.
66. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial:a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
67. O'Byrne PM, Adelroth E. Beta2 deja vu. Chest 2006; 129:3-5.
68. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005; 353:2637-2639.